Advances in the management of thyroid cancer  by Shaha, Ashok R.
International Journal of Surgery (2005) 3, 213e220
www.int-journal-surgery.comREVIEW
Advances in the management of thyroid cancer
Ashok R. Shaha*
Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, United States
KEYWORDS
Thyroid cancer;
Prognostic factors;
Recent advances;
Risk factors in thyroid
cancer
Abstract The incidence of thyroid cancer is rapidly increasing in the United
States. A large number of incidentalomas are found during routine head and neck
evaluations. The diagnostic workup still revolves around fine needle aspiration
biopsy. Ultrasound guided fine needle aspiration biopsy is likely to yield the best
results. Surgical resection offers the best treatment choice. Controversy continues
in relation to total versus less than total thyroidectomy. The incidence of
complications is inversely proportional to the extent of surgery and obviously
related to the experience of the operating surgeon. The decision regarding the
extent of thyroidectomy should be based on prognostic factors and risk groups.
Prognostic factors are well defined, such as age, grade of the tumor, extrathyroidal
extension, size, distant metastasis, and histology. Nodal metastasis has minimal
implications. Based on prognostic factors, thyroid cancer can be divided into low,
intermediate and high risk groups. In the high risk group and in selected
intermediate risk patients, radioactive iodine dosimetry and ablation should be
considered after total thyroidectomy. PET scanning and the use of recombinant TSH
have been major advances in follow-up care for patients with thyroid cancer.
Thyroglobulin appears to be a very good tumor marker for follow-up. No major
breakthrough is noted in the management of anaplastic thyroid cancer, however,
identification of RET mutation has been extremely helpful in evaluating the family
members of the patient with medullary thyroid cancer with strong consideration
given to total thyroidectomy.
ª 2005 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.Introduction
Thyroid cancer incidence has been increasing at
a rate of more than 4% every year for the past 20
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doi:10.1016/j.ijsu.2005.03.012years reports the American Cancer Society. Ap-
proximately 24,000 new patients with thyroid
cancer are seen in the United States annually,
with the most rapid rise in the last few years seen
in women. Despite the steady growth in incidence,
mortality from thyroid cancer has essentially
remained unchanged over the last 20 years. Nearlylished by Elsevier Ltd. All rights reserved.
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however, it is important to note that a majority of
these deaths are related to anaplastic or medul-
lary thyroid carcinoma. Death due to the most
prevalent thyroid cancers, such as papillary and
follicular, is very rare.
The subject of thyroid cancer generates
considerable debate. The major controversies
are related to diagnostic work-up, extent of
thyroidectomy, and postoperative management
including the role of radioactive iodine. Philosoph-
ical differences regarding the management of neck
nodes and evaluation of increased thyroglobulin
add to the controversy.
Approximately 116,000 papers on the subject of
thyroid disease have been published in peer-
reviewed journals, of which 35,000 are related to
thyroid tumors. A Google search reveals more than
2 million sites related to thyroid disease and 1.5
million sites related to thyroid tumors. Clearly,
such a vast volume of literature can easily confuse
any reader. The purpose of this article is to review
the recent advances and discuss the controversies
in the management of thyroid cancer.
Thyroid cancers are generally divided into two
groups: well-differentiated and others. Well-
differentiated tumors comprise over 90% of all
thyroid cancers and demonstrate excellent long
term survival. Types of well-differentiated thyroid
cancer include papillary (the most common),
follicular, Hu¨rthle cell and mixed tumors. These
types are grouped together due to behavioral
similarities. A majority of the mixed group behave
like papillary thyroid carcinomas and those in the
Hu¨rthle cell group like follicular thyroid cancers.
The non-well-differentiated or ‘‘other’’ group
commonly refers to medullary carcinoma of the
thyroid, lymphoma, anaplastic thyroid cancer and
certain rare tumors of the thyroid such as sarcoma,
squamous cell carcinoma and metastatic tumors to
the thyroid. Tumor sites metastasizing to the
thyroid include breast, lung, kidney andmelanoma.
However, isolated metastatic disease to the
thyroid is rare in the absence of other distant
metastasis. Medullary carcinoma of the thyroid
has been found to have a high incidence of
genetic predilection. It forms a part of the MEN
syndrome with an autosomal dominant pene-
trance. The recent advances in molecular biology
have helped us to define the RET mutation in
index patients with medullary carcinoma of the
thyroid. If the presenting patient has the RET
mutation, it is vital to study other family members
(particularly children and siblings), for RET muta-
tion. If the mutation is present, the chance of
developing medullary carcinoma is very high andsuch individuals should undergo prophylactic thy-
roidectomy. This is one of the few human cancers
where the diagnosis of anticipated cancer can be
made based on genetic aberrations.
Diagnostic work-up
A variety of diagnostic tests are available in the
evaluation of a patient presenting with a thyroid
nodule. These include clinical examination, thy-
roid function tests, thyroid scan, ultrasound of the
thyroid, CT and MRI scan, and fine needle aspira-
tion biopsy.
The crucial test in determining the management
of thyroid nodules is fine needle aspiration biopsy,
which should be the first diagnostic test per-
formed. The FNA has a high degree of accuracy
(exceeding 95%), sensitivity and specificity. Needle
biopsy will assist in deciding whether the patient
needs surgical intervention or may be followed
without surgery.1e4
It is, however, important to understand the
pitfalls of needle biopsy and avoid carte blanche
decisions based on the results of the needle biopsy
alone. It is very difficult to make a diagnosis of
follicular carcinoma or minimally invasive follicu-
lar carcinoma based on fine needle aspiration
biopsy alone. The distinction between a benign
follicular adenoma and a malignant follicular
lesion is made based on evaluation of the entire
capsule which cannot be performed on fine needle
aspiration biopsy or frozen section. The size of the
follicular lesion plays an important role in man-
agement decisions. The incidence of malignancy in
patients with thyroid nodules larger than 3 cm is
approximately 30%. Generally with suspicious fol-
licular lesions on fine needle aspiration biopsy,
surgical intervention is recommended. The pres-
ence of Hu¨rthle cells in fine needle aspiration
cytology is difficult to evaluate and often leads to
the diagnosis of a Hu¨rthle cell neoplasm. Generally
surgical intervention is recommended for such
patients.6
Various investigators have tried to use immuno-
histochemistry and molecular biology to interpret
fine needle aspiration biopsy results to distinguish
suspicious thyroid lesions. A variety of studies
using galactin and telomerase have been attemp-
ted; however, they have not yet been shown to be
of practical value. The future of diagnostic eval-
uation of thyroid nodules rests, in my mind, on
application of an appropriate molecular marker to
the specimen from fine needle aspiration cytology,
which can be made cost effective and user
friendly.
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nodule is hypofunctioning or hyperfunctioning.
The incidence of malignancy in hyperfunctioning
(hot) thyroids is very low (less than 5%), while the
incidence of malignancy in cold thyroid nodules
ranges between 15 and 30% depending upon the
selection for surgical intervention.
A thyroid ultrasound is commonly used to de-
termine whether a thyroid nodule is solid or cystic.
The incidence of malignancy in solid thyroid
nodules is approximately 20%, while the incidence
of malignancy in cystic nodules is less than 4%.
Ultrasonographic findings including punctate cal-
cification, irregular margins, lack of halo, and
infiltration into the surrounding structures, or
suspicious neck nodes are highly suspicious for
malignancy. Appropriate consideration should be
given to possible surgical intervention or evalua-
tion with fine needle aspiration biopsy.
Although a CT or MRI is not of great value in
evaluating a classic thyroid nodule, a CT is helpful
in patients presenting with large thyroid masses,
those fixed to the central compartment or adher-
ent to the trachea and surrounding structures, or
in cases of vocal cord paralysis. A CT scan will
define the extent of the thyroid tumor and whether
intratracheal invasion has occurred. It is impor-
tant to perform the CT scan without contrast to
avoid injection of iodinated dye, which delays
radioactive iodine treatment after surgery.
Patients presenting with large substernal goiters,
anaplastic thyroid cancer or suspected lymphoma
are best evaluated with CT scan to define the
extent of the disease, location of the trachea,
and status of the airway.5e8
Incidentalomas of the thyroid
Various diagnostic advances along with routine
imaging studies performed for neck problems have
recently increased the number of incidentalomas
of the thyroid diagnosed. The overall incidence of
thyroid nodularity in the general population ex-
ceeds 10%, and is noted in 40e50% of older
individuals. Unfortunately, it is still almost
impossible to prove or disprove a malignant
lesion requiring further intervention. Thyroid
incidentalomas can be divided into two groups:
clinical, found during routine evaluation for other
medical problems and imaging incidentalomas
found on ultrasound (commonly performed for
carotid artery), CT scan (performed for neck and
spine problems and vehicular accidents), and MRI
(commonly performed for neurological evaluation
and headache). The routine utility of the PET scanfor other neoplastic diseases has increased the
detection of PET incidentalomas of the thyroid.
The intense and hypermetabolic activity of FDG
in the thyroid nodule leads to some concern about
the evaluation of thyroid pathology. A majority of
the thyroid nodules which are not suspicious on
ultrasound (less than 1 cm in dimension) can be
easily followed and generally do not require
further intervention except vigilant follow-up. An
ultrasound is generally repeated at intervals of
6e12 months to look for any major change in the
size of the thyroid nodule. The majority of in-
cidentalomas larger than 1 cm in size are commonly
evaluated with ultrasound and ultrasound-guided
fine needle aspiration biopsy. Once again, if the
fine needle aspiration biopsy is positive or suspi-
cious, the patients will require surgical interven-
tion. Otherwise, most of the incidental thyroid
nodules can be easily followed with serial ultra-
sounds of the thyroid.
Surgical management of thyroid cancer
There appears to be considerable controversy
regarding surgical management of thyroid cancer.
The issue revolves around the routine use of total
thyroidectomy versus less than total thyroidectomy.
There are strong proponents and opponents of
routine total thyroidectomy for management of
thyroid tumors. Before discussing the issue of the
extent of thyroidectomy, it is vital to understand
the prognostic factors and risk group analysis in
well-differentiated thyroid cancer.
Our understanding of thyroid cancer has im-
proved considerably over the last two decades with
identification of prognostic factors. The Mayo Clinic
defined prognostic factors as AGES (Age, Grade of
the tumor, Extrathyroidal extension and Size of the
tumor). A specific scoring system was devised
showing excellent outcome in patients scoring less
than 3.99. The Lahey Clinic also defined similar
prognostic factors, described as AMES (Age, distant
Metastasis, Extrathyroidal extension and Size of the
tumor). A variety of prognostic schemes were de-
veloped such as EORTC, Memorial Sloan-Kettering
Cancer Center, AJCC-UICC, and DeGroot Classifica-
tion. The basic philosophy of these prognostic
indicators remains the same; the most important
prognostic factors are age, size of the tumor,
extrathyroidal extension, distant metastasis, the
appropriate histopathology and grade of the tumor.
Other prognostic factors such as nodal metastasis,
sex and multicentricity of thyroid tumor did not
have a major impact on the long term outcome in
multivariate analysis.9e15
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tic factor in patients with well-differentiated
thyroid cancer. In patients below the age of 45,
there are only two stages in the classification of
thyroid cancer: Stage I and Stage II. Even with
pulmonary metastasis in young individuals, the
patients are classified as Stage II, not as Stage IV.
This is primarily related to the excellent outcome
in young individuals, even with advanced thyroid
cancer. This is the only human cancer where age is
included in the parameters of the staging system.
Clearly, this is a unique biological feature of
thyroid cancer which needs to be understood in
terms of the overall management of patients with
well-differentiated thyroid cancer.
Another unique feature of thyroid cancer is the
lack of impact from nodal metastasis. The fre-
quent incidence of nodal metastasis, especially in
papillary carcinoma of the thyroid in young indi-
viduals, does not change the prognosis. In most
other human cancers regional and nodal metasta-
sis diminishes survival by approximately 50%.
However, in papillary carcinoma of the thyroid, it
has no major impact on long term outcome except
in older individuals or in patients with poorly-
differentiated thyroid cancer.
The presence of extrathyroidal extension of
well-differentiated thyroid cancer is an important
prognostic factor which should be recognized and
managed during the initial surgery. The involve-
ment of surrounding structures such as strap
muscles, the recurrent laryngeal nerve, tracheal
wall, and esophageal musculature is extremely
important. Every effort to remove all gross tumors
must be made, since gross or macroscopic tumor
left behind will cause the patient to develop local
recurrence and the chances of surgical salvage will
diminish by almost 50%. Generally, locally aggres-
sive thyroid cancers in the central compartment
are more common in older individuals and are more
likely to be associated with adverse histopatholog-
ical features such as poorly-differentiated thyroid
cancer. There also appears to be a higher incidence
of local recurrence, regional metastasis and distant
metastasis in patients presenting with locally ad-
vanced or extrathyroidal extension of thyroid
tumors. The basic oncologic principle of removal
of all gross tumors should be adhered to in patients
presenting with locally aggressive thyroid cancer.
However, every attempt should be made to pre-
serve the vital structures and functioning organs
such as the trachea, recurrent laryngeal nerve and
larynx. Most of the time, even if the tumor is
adherent to the trachea wall, it can be easily
shaved off the tracheal wall. However, if there is
intraluminal involvement of the trachea, the pa-tient will require sleeve resection of the trachea
and primary end-to-end anastomosis. Based on
these prognostic factors, patients with well-differ-
entiated thyroid cancer can be divided into low and
high risk groups. The outcome in the low risk group
as defined by the data from Mayo Clinic and Lahey
Clinic is 98% long term survival. In the high risk
group the mortality rate is approximately 46%.
Shaha and colleagues at Memorial Sloan-Kettering
Cancer Center divided their risk groups into low,
intermediate and high risk groups. The low risk
group includes low risk patients (generally below
the age of 45) and low risk tumors. The high risk
group includes high risk patients (above the age of
45) and high risk tumors (more aggressive thyroid
tumors). The intermediate risk group is defined as
younger (more favorable) individuals with aggres-
sive thyroid cancer or older individuals with small
thyroid tumors. Based on this risk stratification,
Shaha et al. were able to define the long term
outcome differences in various risk groups. Survival
in the low risk group was 99%, while the survival in
the intermediate and high risk groups were 87 and
57% in their reports.16e18
Management of locally aggressive
thyroid cancer
One of the most difficult problems in the manage-
ment of thyroid cancer is the presence of extra-
thyroidal extension or locally aggressive thyroid
cancer in the central compartment of the
neck.19,20 It is important to remove all gross
tumors during the first surgical procedure and at
the same time maintain all functioning organs. The
functioning recurrent laryngeal nerve should be
preserved as best as possible. This is of more
concern in young individuals where there may be
extensive metastatic disease in the paratracheal
area. If the tumor involves the strap muscles, they
need to be sacrificed. Many times, however, the
tumor can be easily shaved off the tracheal wall
even if the tumor is adherent to the trachea, and
postoperative radioactive iodine can be used as an
effective treatment method. If the tumor infiltrates
the tracheal wall or there is extensive intraluminal
disease, the patient will require segmental resec-
tion and end-to-end anastomosis.19,20 Most of these
patients will need radioactive iodine providing local
control that is quite satisfactory. However, if the
tumor recurs locally, the chances of salvaging the
anatomic structures are much smaller. There is
clearly a high incidence of local recurrence, regional
metastasis and distant metastasis in patients with
extrathyroidal extension of the disease.
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There is a very high incidence of nodal metastasis
in patients with papillary carcinoma of the thyroid.
However, clinically apparent nodal metastasis is
seen only in 30e40% of these individuals. The
elective nodal dissection is not indicated in
patients with well-differentiated thyroid cancer;
however, during the initial surgical procedure
routine paratracheal evaluation and paratracheal
clearance should be undertaken. Central compart-
ment clearance is a routine surgical procedure in
patients with papillary carcinoma of the thyroid.
The lateral neck dissection is performed only if
gross nodal metastasis is noted at the time surgery
along the jugular vein or clinically palpable nodal
metastases are noted in the lateral neck. Elective
lateral neck dissection is generally not indicated in
patients with papillary carcinoma of the thyroid.
A majority of patients with nodal metastasis will
require postoperative radioactive iodine and
should be followed closely to rule out any re-
current nodal disease. The presence of nodal
metastasis has very little clinical implication in
the long term outcome. However, in older individ-
uals, especially with poorly-differentiated thyroid
cancer, nodal metastasis appears to have signifi-
cance, mainly in relation to multiply recurrent
disease in the neck requiring several surgical
procedures and rare transformation into a more
aggressive form of thyroid cancer. Young individu-
als presenting with massive nodal metastases are
more likely to have pulmonary metastases which
are best identified with radioactive iodine ablation
and those young patients with bulky nodal metas-
tases should undergo total thyroidectomy and
appropriate radioactive iodine treatment to de-
tect pulmonary metastasis. Pulmonary metastases
are best treated when they are microscopic rather
than gross metastatic disease in the lungs. The
outcome in these individuals is excellent and there
is rarely any concern about long term survival.20e27
Histopathology
Thyroid cancer presents as a spectrum of dis-
eases. The same human organ has at one end of
the spectrum the cancers with the best prognosis,
which are papillary and follicular carcinoma of
the thyroid with overall survival exceeding 90%,
while at the other end of the spectrum there are
cancers with the worst prognosis, which are
undifferentiated and anaplastic thyroid carcino-
ma. It is interesting to appreciate that there is
a diagnosis inbetween called poorly-differentiatedthyroid carcinoma. This histopathological entity
presents in various forms, such as tall cell thyroid
carcinoma, trabecular, insular columnar, etc. Un-
derstanding of this histologic variation is crucial
because a majority of these tumors are commonly
seen in older people who present more often with
extrathyroidal extension, which are often more
aggressive tumors that are non-radio avid and
need a PET scan for follow-up. Patients present-
ing with poorly-differentiated thyroid carcinoma
need very close follow-up and aggressive surgery
as there appears to be a higher incidence of local
recurrence and distant metastasis in this group,
presenting with extrathyroidal extension.
Postoperative management
The mainstay of management of well-differenti-
ated thyroid cancer continues to be surgical inter-
vention. Even though there is considerable
debate about total versus less than total thyroid-
ectomy, in high risk group patients, total thyroid-
ectomy is most beneficial along with adjuvant
treatment. Several advances have been noted
recently in the postoperative management of
patients with thyroid cancer. One of the major
advances is the availability of recombinant TSH.
The indications for postoperative radioactive
iodine treatment include ablation of the residual
thyroid tissue after total thyroidectomy, and
either residual thyroid cancer or identification of
regional or distant metastasis. Once the patient
has undergone total thyroidectomy, the patient
should remain off thyroid medication over a period
of six weeks in order to maintain a hypothyroid
condition. During this time, Cytomel may be used
for a short period of time. Once the patient is
made adequately hypothyroid with a TSH level
of about 25 units, radioactive iodine dosimetry
should be performed with an initial dose of 2e
5 mCi and subsequently treated with a larger dose.
The latter dose used to be the outpatient dose of
30 mCi. Recently, there has been a major paradigm
shift in the postoperative management of patients
with thyroid cancer. This includes the availability
of recombinant TSH. Two injections of recombi-
nant TSH can be given to raise the TSH level. Once
the TSH level is high, within 24e48 h, radioactive
iodine dosimetry can be performed again with
2e5 mCi. In some select circumstances when the
TSH is still high, an opportunity can be taken to
treat the patients with a larger dose of radioactive
iodine. A larger dose equivalent to 75e100 mCi can
be given on an outpatient basis. Renal clearance
should be evaluated in every patient to determine
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a larger dose is generally used both to identify the
distant metastases and to treat them effectively.25
It is not uncommon that radioactive iodine dosim-
etry fails to document a small amount of distant
metastatic disease which can be effectively seen
and treated with a larger dose of radioactive
iodine. Most of the time, the dose may need to
be repeated depending upon the initial findings.
Patients who are treated with radioactive iodine
and noted to have metastatic disease in the lung
respond extremely well, especially young children.
Pulmonary metastatic disease which is not seen on
chest X-ray but noted on radioactive iodine re-
sponds very well. The presence of distant metas-
tasis to the liver or bone generally in this group
presenting with extrathyroidal extension not re-
spond very well. Sugitani et al.26 recently reported
major prognostic factors in the postoperative
period, which include the size and number of
nodal metastases. The larger the volume of nodal
metastases, the higher is the risk of distant
metastasis. They also noted that a majority of
the distant metastases were seen in the first three
years of the postoperative period.
Another major innovation is the utility of PET
scanning in follow-upofpatientswith thyroid cancer.
PET scanning is more important in older patients,
poorly-differentiated thyroid cancers and non-radio
avid thyroid tumors. The patients in whom radioac-
tive iodine is not effective are adequately studied
with a PET scan, particularly with FDG uptake. PET
positive metastatic disease behaves much more
aggressively compared to PET negative disease.
There appears to be a much better understand-
ing of thyroid suppressive therapy and its effect on
the long term outcome of patients with thyroid
cancer. Most patients with well-differentiated
thyroid cancer should be maintained on an ade-
quate dosage of thyroid medication to keep their
TSH low. The TSH is maintained below 0.5 units;
undetected TSH is not considered to be ideal since
there is a high incidence of these patients de-
veloping osteoporosis. The patients who do not
respond well to radioactive iodine treatment have
been recently studied with the use of lithium,
Vitamin A analogue, or I-124 to potentiate the
effects of radioactive iodine treatment.
Medullary thyroid carcinoma of the
thyroid
Several points should be noted in the diagnostic
evaluation and management of patients withmedullary carcinoma of the thyroid. Calcitonin
continues to be an important tumor marker in
these patients; however, understanding of the
molecular biology of this disease has revolution-
ized the approach towards evaluating family mem-
bers with medullary carcinoma of the thyroid.
Medullary carcinoma of the thyroid is a familial
disease with autosomal dominant penetrance.
Whenever a patient is noted to have medullary
carcinoma of the thyroid, it is important to review
the family history and evaluate family members
with RET mutation studies. If the patient has a RET
mutation, especially in Codon 610, family mem-
bers (particularly siblings and children) should be
evaluated. If one of the children has a similar
mutation, a prophylactic total thyroidectomy
should be considered. Generally, this is preferable
at the age of 5e7 years, however in patients
suspected of having MEN 2b, a total thyroidectomy
should be considered earlier since these individu-
als will invariably go on to develop medullary
carcinoma of the thyroid. This is one of the few
conditions in the human body where a prophylactic
surgical procedure is undertaken to prevent de-
velopment of malignant tumor. It is, however,
important to appreciate the complications of total
thyroidectomy, especially in young individuals,
mainly related to permanent hypoparathyroidism
and nerve injury.
The standard treatment for patients presenting
with medullary carcinoma of the thyroid is total
thyroidectomy and appropriate nodal clearance.
Central compartment clearance is routinely per-
formed in most patients from jugular vein to
jugular vein. If there are clinically apparent nodal
metastases, ipsilateral or bilateral modified neck
dissection should be considered. Patients with
medullary carcinoma of the thyroid need to be
followed carefully, especially their calcitonin level.
Rising calcitonin indicates recurrence of medullary
carcinoma of the thyroid which invariably is noted
in the cervical lymph nodes or superior mediastinal
lymph nodes. Appropriate evaluation of persistent
or rising calcitonin levels requires proper imaging
studies, such as ultrasound of the neck, CT or MRI
scan, PET scan or octreotide scan. The patient who
presents with massive hypercalcitonemia may
have liver metastasis which may be difficult to
see with routine imaging studies. These patients
are best evaluated with laparoscopy and laparo-
scopic-guided needle aspiration biopsy of the
surface of the liver where there may be tiny
surface nodularity representing metastatic medul-
lary carcinoma of the thyroid. Several experimen-
tal protocols are being evaluated for management
of recurrent medullary carcinoma of the thyroid.
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undefined at this time in the management of
medullary carcinoma of the thyroid.
Anaplastic thyroid cancer
One of the major challenges in the management of
thyroid cancer continues to be anaplastic thyroid
cancer. This is probably one of the most aggressive
human cancers, where average survival is counted
in months rather than years and five year survival
is in the low single digits. Most patients present
with a rapidly growing mass in the thyroid region,
essentially freezing the entire central compart-
ment of the neck. Almost 50% of the patients
present with regional or distant metastasis. Occa-
sionally, the patient may present with a rapidly
growing thyroid mass, hoarseness of voice and
difficulty in breathing, suggestive of extensive
tumor in the central compartment and possible
bilateral vocal cord paralysis. Appropriate man-
agement of these patients includes definitive di-
agnosis, either with a core biopsy or open biopsy of
the thyroid. Core biopsy is generally quite suffi-
cient. Using appropriate immunohistochemistry, it
is important to rule out small cell anaplastic
thyroid cancer and lymphoma. Once a diagnosis
of anaplastic thyroid cancer (giant and spindle cell
anaplastic thyroid cancer) is made, these patients
are best treated with a combination of chemo-
therapy and radiation therapy. Adriamycin along
with radiation therapy has shown some promising
results; however, overall the response to the
treatment is still quite poor. Most of the time
satisfactory surgical resection is unlikely; however,
in a select group of patients, surgery may be
undertaken if the tumor appears to be well-
localized. Experimental therapeutic trials are
ongoing with the use of thalidomide, anti-angio-
genesis factors and somatostatin analogs. The
results of these experimental therapies are still
being reviewed. Hyperfractionated radiation ther-
apy and IMRT may be much more beneficial and
targeted.
Conclusions
There appears to be a considerable rise in the
incidence of thyroid cancer, especially in women
in the recent years. The diagnostic evaluation of
a patient presenting with thyroid nodules revolves
around fine needle aspiration biopsy with appropriate
understanding of its limitations. Even though there isdebate related to the extent of thyroidectomy, it is
important to analyze the prognostic factors and risk
group strategies in any decision. The therapeutic
approaches should be chosen based upon the extent
of disease and risk group analysis. The long term
survival in low, intermediate and high risk groups is
reported to be 99, 87 and 57%, respectively. Appro-
priate surgical intervention necessitates understand-
ing of extrathyroidal extension of the disease and
proper surgical management for the same. Under-
standing of poorly-differentiated thyroid cancer in
relation to its non-radio avidity, aggressive clinical
behavior and PET positivity are some of the innova-
tions seen in the recent years. The role of recombinant
TSH appears to have changed the quality of life in
patients undergoing radioactive dosimetry and abla-
tion. These patients do not need to bemade hypothy-
roid anymore. In spite of several changes and better
control of thyroid cancer, anaplastic thyroid cancer
continues to be a major challenge. Future issues
include defining appropriate molecular markers to
recognize the aggressiveness of thyroid cancer based
on a fine needle aspiration biopsy specimen and
continuing management of anaplastic thyroid cancer.
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